Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercise, open-market sale and related holdings on Form 4. On 09/18/2025 he exercised 3,763 non-qualified stock options at an $86.09 exercise price, receiving 3,763 shares. The same day he sold 5,097 shares at $290 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024. After these transactions he beneficially owned 44,371 shares (before the sale) and 39,274 shares (after the sale), with 3,763 shares exercisable from previously granted options. The Form was signed by an attorney-in-fact on 09/22/2025.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported transactions on 09/16/2025. The filing shows a sale of 31,350 common shares executed under a Rule 10b5-1 plan adopted 11/25/2024 at a weighted average price of $289.861 (tranche prices ranged from $287.372 to $292.625). The form also records an acquisition (code M) of 29,350 shares tied to a non-qualified stock option with an exercise price of $86.09, exercisable in four equal annual installments beginning 11/13/2020 and expiring 11/13/2026. Following the reported transactions, the reporting person beneficially owned 305,912.665 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Collis on 09/18/2025.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 5,097 common shares through Fidelity Brokerage Services on 09/18/2025 with an aggregate market value of $1,478,130.00. The document shows total shares outstanding of 193,877,881. Acquisition details list 1,334 shares from restricted stock vesting on 09/30/2023 recorded as compensation, and 3,763 shares from options (granted 11/13/2019) transacted 09/18/2025 for cash. The filing also discloses three prior sales by Robert P. Mauch on 06/18/2025, 07/18/2025 and 08/18/2025 of ~4,968–4,969 shares each with gross proceeds shown. Several identifying fields for the filer and issuer are not provided in the text.
Form 144 notice for Cencora, Inc. (COR) records a proposed sale of 31,350 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $9,140,092.50 and an approximate sale date of 09/16/2025. The filing breaks the lot into 2,000 shares acquired on 09/30/2023 by restricted stock vesting (compensation) and 29,350 shares tied to options granted on 11/13/2019 with a payment date of 09/16/2025 identified as cash.
The form also lists three recent insider sales by Steven Collis: 14,579 shares on 06/24/2025 for $4,266,106.98, 14,578 shares on 07/22/2025 for $4,266,543.26, and 14,579 shares on 08/19/2025 for $4,227,618.42. The notice includes the mandatory representation that the seller is not aware of undisclosed material adverse information.
Cencora, Inc. filed a Form 8-K reporting entry into material agreements. The company executed Amendment No. 2 to the Term Credit Agreement dated September 5, 2025, among the company, the lenders party thereto, and Bank of America, N.A. as administrative agent. On the same date it executed Amendment No. 2 to an Uncommitted Money Market Line Credit Agreement dated September 5, 2025, between the company and Société Générale, New York Branch as lender. The filing references the company's common stock (NYSE: COR), two series of senior notes (2.875% due 2028 and 3.625% due 2032), and certain solicitation and pre-commencement communication rules. The cover page interactive data file is embedded within the Inline XBRL document.
Cencora, Inc. reported that it has reached an agreement, subject to court approval, to resolve a stockholder derivative lawsuit in the Delaware Court of Chancery. The case, brought by Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan, alleges breaches of fiduciary duty related to oversight of the company’s controlled substance diversion control programs.
Under a Stipulation and Agreement of Settlement filed on August 15, 2025, insurance carriers would pay the company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to the plaintiffs’ counsel, if the Court approves the settlement. The defendants do not admit liability and expressly deny any wrongdoing. The Court has entered a scheduling order and directed the company to file this report, attach the settlement documents, and post them in its investor relations website.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported option exercise and open-market sales on 08/19/2025. He exercised 12,579 non-qualified stock options with an exercise price of $86.09, acquiring 12,579 shares underlying those options. The exercise increased his direct holdings to 322,491.665 shares. On the same date he sold 14,579 shares at $289.98 per share, leaving 307,912.665 shares after the transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on 11/25/2024. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercises and open-market sales on 08/18/2025. He exercised 3,225 non-qualified stock options with an exercise price of $86.09 under a grant that vests in four prior annual installments, and those options produced 3,225 shares recorded as acquired. The same day he sold 4,968 shares at $293.53 per share pursuant to a Rule 10b5-1 trading plan adopted 11/15/2024. After these transactions he beneficially owned 40,608 shares and held 22,577 derivative securities (options) reported as direct ownership.
Cencora, Inc. (COR) Form 144 shows proposed and recent insider sales of common stock by Steven Collis. The filing notifies a brokered proposed sale of 14,579 shares with an aggregate market value of $4,227,618.42 scheduled for 08/19/2025 on the NYSE through Fidelity Brokerage Services. The filing also discloses the acquisition history for the shares to be sold: 2,000 shares from restricted stock vesting on 09/30/2023 (compensation) and 12,579 shares from an option exercise dated 08/19/2025 (cash).
Separately, three insider sales by Steven Collis during the past three months are reported: 14,578 shares on 05/20/2025 for $4,283,599.52, 14,579 shares on 06/24/2025 for $4,266,106.98, and 14,578 shares on 07/22/2025 for $4,265,100.54. The filing includes the seller's representation about lack of undisclosed material information and a signature notice regarding legal penalties for misstatement.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
